Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Accelerated corneal collagen cross-linking in keratoconus patients with Down syndrome

Poster Details

First Author: M.Taskapili TURKEY

Co Author(s):    Y. Yildirim   A. Agca   B. Kepez Yildiz   O. Olcucu   S. Genc   M. Arici     

Abstract Details


To evaluate the effect of accelerated corneal collagen crosslinking (A-CXL) used as a treatment option in Down syndrome patients with progressive keratoconus.


Beyoglu Eye Training and Research Hospital


Forty-six eyes of 23 Down syndrome patients with progressive keratoconus data were retrospectively reviewed. Thirty-six eyes of 21 patients who intended accelerated (18 mW/cm(2), 365-nm ultraviolet-A light, 5 minutes) collagen crosslinking (CXL) included this study. Main outcome measures were change in keratometry, uncorrected visual acuity (UCVA), and best-corrected visual acuity (BCVA). Also preoperative and postoperative endothelial cell count and central corneal thickness (CCT)were evaluated. All adverse events were also documented.


The mean age of all patients (10 women and 11 men) was 21.40 �Â�± 4.20 years (range: 18 to 25 years). UDVA improved from 0.70 �Â�± 0.38 to 0.65 �Â�± 0.40 logMAR (P = .062) at the postoperative one year visit. At the last follow-up visit, the flat keratometry decreased from 48.84 �Â�± 3.60 to 48.32 �Â�± 2.92 D, steep keratometry decreased from 53.55 �Â�± 5.12 to 52.86 �Â�± 4.40 D, and apex keratometry decreased from 59.84 �Â�± 5.60 to 59.32 �Â�± 6.50 D (P = .072, = .055, = .060, respectively) from baseline.


The findings of this study revealed that A-CXL treatment effective and safe option in Down syndrome patients with progressive keratoconus.

Financial Disclosure:


Back to Poster listing